Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that it has entered into a license and commercialization agreement with UNILAB, INC. (“UNILAB”), a Philippine company, for its denosumab injections, 9MW0311 (Prolia® biosimilar) and 9MW0321 (Xgeva® biosimilar). Under the agreement, UNILAB will be responsible for the registration and marketing of the products in the Philippines,  while Mabwell will be responsible for the development, manufacturing and commercial supply of the products.

Mabwell has announced collaboration for its denosumab injections in dozens of countries, including Brazil, Colombia, Indonesia, Singapore, Pakistan, Thailand, Egypt, and Saudi Arabia. It has passed the GMP inspection by the National Institute of Food and Drug Administration of Colombia (INVIMA) for its denosumab injections. Phase III study results of 9MW0321 and 9MW0311 were published in the top-tier oncology journal JAMA Oncology and world-renowned journal Expert Opinion on Oncology, respectively.

UNILAB is a leading pharmaceutical company in the Philippines, specializing in the marketing and distribution of high-quality new drugs in the Philippine market. According to IQVIA, UNILAB ranks first among pharmaceutical companies in the Association of Southeast Asian Nations (ASEAN) for its robust manufacturing, registration and marketing capabilities. Both parties entered into a strategic cooperation in August 2023 for adalimumab injection, which is currently in the process of registration in the Philippines.

Hu Huiguo, Director, Senior Vice President and Secretary of the board of Mabwell, said: "We are very delighted to collaborate with UNILAB once again. Both parties are committed to advancingthe registration and commercialization of denosumab injections in the Philippines，just as we successfully did with adalimumab in our previous partnership. We are convinced that this deepened collaboration will further expand Mabwell's presence in the vast ASEAN market and benefit more patients in the Philippines."